Table 3

Independent predictors of MM-or-better-5mg for ≥6 months identified by multivariate logistic modelling

ParametersOR (95% CI), P value
After 1 yearAfter 2 yearsAfter 3 years
EFT2.04 (0.89 to 4.78), 0.092.19 (1.11 to 4.42), 0.02*2.11 (1.03 to 4.44), 0.04*
Early use of CNIs1.59 (0.78 to 3.24), 0.202.09 (1.09 to 4.06), 0.03*2.36 (1.13 to 5.09), 0.02*
Oral PSL dosing regimen
Low-dose/high-dose10.4 (4.54 to 25.2), <0.0001*2.75 (1.31 to 5.88), 0.007*1.86 (0.79 to 4.49), 0.15
Low-dose/intermediate-dose13.4 (5.69 to 34.8), <0.0001*3.99 (1.86 to 8.81), 0.0003*4.92 (2.00 to 12.6), 0.0004*

  • The following variables were also entered in the multivariate logistic model: demographics, antibody status, thymus status, pyridostigmine use, MGFA postintervention status, worst QMG score, accumulated dose of HMP, PE/PP and Ig. Factors that did not show significance after being run through the model are not shown.

  • EFT is use of fast-acting therapy such as PP, often combined with HMP, HMP alone or intravenous Ig within 6 months of treatment initiation.

  • *An independent predictor to achieve the treatment target.

  • CNIs, calcineurin inhibitors; EFT, early fast-acting treatment; HMP, high-dose intravenous methylprednisolone; Ig, immunoglobulin; MGFA, Myasthenia Gravis Foundation of America; MM-or-better-5mg for ≥6 months, minimal manifestation status or better on PSL ≤5 mg/day lasting >6 months (the treatment target); PE/PP, plasma exchange/plasmapheresis; PSL, prednisolone; QMG, quantitative myasthenia gravis.